Waking Up to REMS (Part 3): Redefining Marketing

FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.

By Michael McCaughan

Speakers bureaus. Scripted Medical Science Liaisons. Aggressive sales force goals. Call center support programs. Targeted journal ads. Preferred prescriber agreements....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet